Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

BACKGROUND: This registrational trial evaluated the efficacy, safety, and patient-reported outcomes of axitinib versus sorafenib as a second-line treatment in Asian patients with clear-cell metastatic renal cell carcinoma (mRCC). METHODS: In this open-label, multicenter study, previously treated Asi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Onco Targets Ther
Main Authors: Qin, Shukui, Bi, Feng, Jin, Jie, Cheng, Ying, Guo, Jun, Ren, Xiubao, Huang, Yiran, Tarazi, Jamal, Tang, Jie, Chen, Connie, Kim, Sinil, Ye, Dingwei
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2015
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467642/
https://ncbi.nlm.nih.gov/pubmed/26089686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S83302
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker